← Back to Screener
BioAge Labs, Inc. Common Stock (BIOA)
Price$16.99
Favorite Metrics
Price vs S&P 500 (26W)195.31%
Price vs S&P 500 (4W)-18.17%
Market Capitalization$753.12M
All Metrics
Book Value / Share (Quarterly)$7.74
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.65
Price vs S&P 500 (YTD)25.63%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.34M
EPS Excl Extra (TTM)$-2.04
EPS (Annual)$-1.98
ROI (Annual)-21.44%
Cash / Share (Quarterly)$7.97
ROA (Last FY)-19.85%
EBITD / Share (TTM)$-2.40
Cash Flow / Share (Annual)$-1.45
P/B Ratio2.71x
P/B Ratio (Quarterly)0.76x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-10.91x
ROA (TTM)-22.81%
EPS Incl Extra (Annual)$-1.98
Current Ratio (Annual)12.86x
Quick Ratio (Quarterly)11.69x
3-Month Avg Trading Volume0.65M
52-Week Price Return353.74%
52-Week High$24.00
EPS Excl Extra (Annual)$-1.98
26-Week Price Return199.29%
Quick Ratio (Annual)12.76x
13-Week Price Return-4.93%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)11.87x
Enterprise Value$541.677
Revenue / Employee (Annual)$0
Cash / Share (Annual)$9.88
3-Month Return Std Dev98.55%
Net Income / Employee (TTM)$-1
ROE (Last FY)-22.01%
EPS Basic Excl Extra (Annual)$-1.98
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-2.04
ROI (TTM)-24.57%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)323.91%
Year-to-Date Return28.27%
5-Day Price Return-4.61%
EPS Normalized (Annual)$-1.98
Month-to-Date Return-2.97%
EBITD / Share (Annual)$-2.18
LT Debt / Equity (Annual)0.01x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.04
P/B Ratio (Annual)0.64x
Book Value / Share (Annual)$9.01
Price vs S&P 500 (13W)-5.62%
Beta1.01x
ROE (TTM)-25.09%
52-Week Low$3.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.90
3.91
4.17
4.15
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BIOABioAge Labs, Inc. Common Stock | — | — | — | — | $16.99 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Bioage Labs is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases like obesity by targeting the biology of aging. Its pipeline includes NLRP3 inhibitors and APJ agonists designed to address the underlying mechanisms of age-related metabolic dysfunction.